• +1-646-491-9876
    • +91-20-67278686

    Search

    Thromboembolism - Pipeline Review, H1 2017

    Thromboembolism - Pipeline Review, H1 2017

    • Report Code ID: RW0001689424
    • Category Healthcare
    • No. of Pages 95
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

    When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 3, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

    Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Thromboembolism - Overview
    Thromboembolism - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Thromboembolism - Companies Involved in Therapeutics Development
    Bayer AG
    Cereno Scientific AB
    China Biologic Products Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Gamma Therapeutics Inc
    GlycoMimetics Inc
    Green Cross Corp
    Ionis Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    The International Biotechnology Center (IBC) Generium
    Verseon Corp
    Thromboembolism - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Thromboembolism - Drug Profiles
    alteplase biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    antithrombin III (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    betrixaban - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    edoxaban tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gammarin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GCC-2107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GMI-1271 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-FXIRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lysimab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Thromboembolism - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rivaroxaban - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAP-ANV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRX-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    valporic acid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YG-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Thromboembolism - Dormant Projects
    Thromboembolism - Discontinued Products
    Thromboembolism - Product Development Milestones
    Featured News & Press Releases
    Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
    Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
    Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
    Dec 06, 2016: New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
    Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants
    Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
    Nov 28, 2016: Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH 2016
    Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
    Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
    Nov 14, 2016: Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically III Patients with Extended-Duration Betrixaban
    Nov 07, 2016: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016
    Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016
    Nov 03, 2016: Janssen To Present Data On Rivaroxaban At 58th American Society of Hematology Annual Meeting
    Oct 25, 2016: Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients
    Oct 23, 2016: Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (rivaroxaban) in Treating and Preventing Blood Clots
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Thromboembolism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Thromboembolism - Pipeline by Bayer AG, H1 2017
    Thromboembolism - Pipeline by Cereno Scientific AB, H1 2017
    Thromboembolism - Pipeline by China Biologic Products Inc, H1 2017
    Thromboembolism - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Thromboembolism - Pipeline by Gamma Therapeutics Inc, H1 2017
    Thromboembolism - Pipeline by GlycoMimetics Inc, H1 2017
    Thromboembolism - Pipeline by Green Cross Corp, H1 2017
    Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H1 2017
    Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017
    Thromboembolism - Pipeline by Verseon Corp, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Thromboembolism - Dormant Projects, H1 2017
    Thromboembolism - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Thromboembolism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Bayer AG
    Cereno Scientific AB
    China Biologic Products Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    Gamma Therapeutics Inc
    GlycoMimetics Inc
    Green Cross Corp
    Ionis Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    The International Biotechnology Center (IBC) Generium
    Verseon Corp

    Request for Sample

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//thromboembolism-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments